For the Record - Oct. 2, 2007
Breast cancer drug: A story in Monday’s Health section stated that the medication raloxifene, or Evista, may soon be approved to help prevent breast cancer in high-risk women. In fact, Evista was approved Sept. 14 to reduce the risk of breast cancer in high-risk post-menopausal women and post-menopausal women with osteoporosis.
More to Read
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
